{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:57:57Z","timestamp":1789732677687,"version":"4.0.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.leukres.2017.09.013","type":"journal-article","created":{"date-parts":[[2017,9,25]],"date-time":"2017-09-25T17:17:34Z","timestamp":1506359854000},"page":"104-107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Low Protein Z levels in patients with plasma cell neoplasms are inversely correlated with IL-6 levels"],"prefix":"10.1016","volume":"62","author":[{"given":"O.","family":"Gutwein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Rahimi-Levene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Herzog-Tzarfati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Garach-Jehoshua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Izak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Koren-Michowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2017.09.013_bib0005","doi-asserted-by":"crossref","first-page":"9250","DOI":"10.1073\/pnas.95.16.9250","article-title":"Isolation of a protein Z-dependent plasma protease inhibitor","volume":"95","author":"Han","year":"1998","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.leukres.2017.09.013_bib0010","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1182\/blood-2008-07-171884","article-title":"Unique secretion mode of human protein Z: its Gla domain is responsible for inefficient, vitamin K-dependent and warfarin-sensitive secretion","volume":"113","author":"Souri","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.09.013_bib0015","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1160\/TH09-09-0645","article-title":"A meta-analysis of potential risks of low levels of protein Z for diseases related to vascular thrombosis","volume":"103","author":"Sofi","year":"2010","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.leukres.2017.09.013_bib0020","first-page":"1144","article-title":"Clinical significance of protein Z detection in patients with malignant tumors","volume":"24","author":"Shang","year":"2005","journal-title":"Ai Zheng\u2009=\u2009Aizheng\u2009=\u2009Chin. J. Cancer"},{"key":"10.1016\/j.leukres.2017.09.013_bib0025","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0049-3848(98)00210-2","article-title":"Plasma protein Z levels inversely correlate with plasma interleukin-6 levels in patients with acute leukemia and non-Hodgkin\u00dcs lymphoma","volume":"94","author":"\u00dcndar","year":"1999","journal-title":"Thromb. Res."},{"key":"10.1016\/j.leukres.2017.09.013_bib0030","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/MBC.0b013e32835d06f1","article-title":"The evaluation of protein Z levels of children with acute lymphoblastic leukaemia during induction therapy","volume":"24","author":"\u00c7ankal","year":"2013","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.leukres.2017.09.013_bib0035","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1177\/1076029611429784","article-title":"Protein Z concentrations in patients with acute leukemia","volume":"18","author":"Galar","year":"2012","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"10.1016\/j.leukres.2017.09.013_bib0040","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1002\/ijc.30020","article-title":"Protein Z: a putative novel biomarker for early detection of ovarian cancer","volume":"138","author":"Russell","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.leukres.2017.09.013_bib0045","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s11239-008-0199-9","article-title":"Intron F G79A polymorphism of the protein Z gene in cancer patients with and without thrombosis","volume":"27","author":"Eroglu","year":"2009","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.leukres.2017.09.013_bib0050","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1182\/blood-2014-11-568881","article-title":"Pathogenesis beyond the cancer clone(s) in multiple myeloma","volume":"125","author":"Bianchi","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.09.013_bib0055","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-2141.2008.07577.x","article-title":"Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias","volume":"145","author":"Eby","year":"2009","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2017.09.013_bib0060","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jri.2005.03.005","article-title":"Validation and comparison of luminex multiplex cytokine analysis kits with ELISA: determinations of a panel of nine cytokines in clinical sample culture supernatants","volume":"66","author":"Wang","year":"2005","journal-title":"J. Reprod. Immunol."},{"key":"10.1016\/j.leukres.2017.09.013_bib0065","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s12185-011-0846-3","article-title":"Protein Z is present in human breast cancer tissue","volume":"93","author":"Sierko","year":"2011","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.leukres.2017.09.013_bib0070","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1016\/j.thromres.2011.09.005","article-title":"Protein Z\/protein Z-dependent protease inhibitor system in human non-small-cell lung cancer tissue","volume":"129","author":"Sierko","year":"2012","journal-title":"Thromb. Res."},{"key":"10.1016\/j.leukres.2017.09.013_bib0075","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00277-013-1941-8","article-title":"Protein Z\/protein Z-dependent protease inhibitor system in loco in human gastric cancer","volume":"93","author":"Sierko","year":"2014","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2017.09.013_bib0080","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1016\/j.thromres.2011.10.027","article-title":"Co-localization of Protein Z, Protein Z-Dependent protease inhibitor and coagulation factor X in human colon cancer tissue: implications for coagulation regulation on tumor cells","volume":"129","author":"Sierko","year":"2012","journal-title":"Thromb. Res."},{"key":"10.1016\/j.leukres.2017.09.013_bib0085","first-page":"1","article-title":"Quantification of protein Z expression in lung adenocarcinoma tissues and cells","volume":"5","author":"Wang","year":"2016","journal-title":"SpringerPlus"},{"key":"10.1016\/j.leukres.2017.09.013_bib0090","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/bjc.2017.199","article-title":"A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive Type II tumours","volume":"117","author":"Russell","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.leukres.2017.09.013_bib0095","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.thromres.2011.07.040","article-title":"Protein Z concentration in multiple myeloma patients","volume":"128","author":"Bolkun","year":"2011","journal-title":"Thromb. Res."},{"key":"10.1016\/j.leukres.2017.09.013_bib0100","series-title":"Thrombosis in Multiple Myeloma (MM)","author":"Cesarman-Maus","year":"2012"},{"issue":"Suppl. 1","key":"10.1016\/j.leukres.2017.09.013_bib0105","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/S0049-3848(12)70024-5","article-title":"Risk and management of thrombosis in multiple myeloma","volume":"129","author":"Leebeek","year":"2012","journal-title":"Thromb. Res."},{"key":"10.1016\/j.leukres.2017.09.013_bib0110","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1055\/s-2007-976169","article-title":"Hemostatic dysfunction in paraproteinemias and amyloidosis","volume":"33","author":"Zangari","year":"2007","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.leukres.2017.09.013_bib0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2016.07.006","article-title":"Revisiting IL-6 antagonism in multiple myeloma","volume":"105","author":"Matthes","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.leukres.2017.09.013_bib0120","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1038\/leu.2015.145","article-title":"Autocrine amplification of immature myeloid cells by IL-6 in multiple myeloma-infiltrated bone marrow","volume":"29","author":"Matthes","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2017.09.013_bib0125","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1055\/s-0037-1613003","article-title":"Weak regulation of protein Z biosynthesis by inflammatory cytokines","volume":"87","author":"Vasse","year":"2002","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.leukres.2017.09.013_bib0130","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1042\/CS20110340","article-title":"IL-6\/IL-6 receptor system and its role in physiological and pathological conditions","volume":"122","author":"Mihara","year":"2012","journal-title":"Clin. Sci."},{"key":"10.1016\/j.leukres.2017.09.013_bib0135","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1365-2141.2001.03061.x","article-title":"Interleukin 6 and haemostasis","volume":"115","author":"Kerr","year":"2001","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2017.09.013_bib0140","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/MBC.0b013e3280124f2c","article-title":"Modifications of protein Z and interleukin-6 during the acute phase of coronary artery disease","volume":"18","author":"Cesari","year":"2007","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.leukres.2017.09.013_bib0145","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1159\/000354194","article-title":"Impact of interleukin-6 in hematological malignancies","volume":"40","author":"Burger","year":"2013","journal-title":"Transfus. Med. Hemother."},{"key":"10.1016\/j.leukres.2017.09.013_bib0150","doi-asserted-by":"crossref","first-page":"5736","DOI":"10.1128\/MCB.10.11.5736","article-title":"On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: enhancer, TATA box, and RNA start site (Inr motif) occlusion","volume":"10","author":"Ray","year":"1990","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.leukres.2017.09.013_bib0155","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood.V84.9.3063.3063","article-title":"Interleukin-6 prevents dexamethasone-induced myeloma cell death","volume":"84","author":"Hardin","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.09.013_bib0160","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1586\/14737140.7.3.307","article-title":"Thrombosis in multiple myeloma","volume":"7","author":"Zangari","year":"2007","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.leukres.2017.09.013_bib0165","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1182\/blood-2008-02-141614","article-title":"Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure","volume":"112","author":"Wang","year":"2008","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212617305210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212617305210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,18]],"date-time":"2020-10-18T06:32:41Z","timestamp":1603002761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212617305210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":33,"alternative-id":["S0145212617305210"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2017.09.013","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low Protein Z levels in patients with plasma cell neoplasms are inversely correlated with IL-6 levels","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2017.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}